Dying of brain tumours: Specific aspects of care

Current Opinion in Supportive and Palliative Care

Volumn 7, Issue 4, 2013, Pages 417-423

  Steigleder, Tobias ^a,b   Stiel, Stephanie ^a   Ostgathe, Christoph ^a  

^a Department of Palliative Medicine   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Brain tumour; End of life; Palliative care; Quality of life

Indexed keywords

BRAIN TUMOR; CAREGIVER; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; DECISION MAKING; DEPRESSION; FATIGUE; HUMAN; MEDLINE; METHODOLOGY; NEEDS ASSESSMENT; PALLIATIVE THERAPY; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; STANDARD; TERMINAL CARE;

BRAIN NEOPLASMS; CAREGIVERS; CENTRAL NERVOUS SYSTEM DISEASES; COGNITION DISORDERS; DECISION MAKING; DEPRESSION; FATIGUE; HUMANS; NEEDS ASSESSMENT; PALLIATIVE CARE; PROGNOSIS; PUBMED; QUALITY OF LIFE; TERMINAL CARE;

EID: 84887987378     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32836575f9     Document Type: Review

References (66)

1. Sizoo EM, Pasman HR, Buttolo J, et al. Decision-making in the end-oflife phase of high-grade glioma patients. Eur J Cancer 2012; 48:226-232.
2. Ostgathe C, Gaertner J, Kottarba M, et al. Differential palliative care issues in patients with primary and secondary brain tumours. Support Care Cancer 2010; 18:1157-1163.
3. Madsen K, Poulsen HS. Needs for everyday life support for brain tumour patients' relatives: systematic literature review. Eur J Cancer Care (Engl) 2011; 20:33-43.
4. Pignatti F, van den Bent MJ, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002; 20:2076-2084.
5. Puduvalli VK, Hashmi M, Mc Allister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 2003; 65:259-266.
6. Stupp R, Mason WP, Van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
7. Jenkinson MD, Haylock B, Shanoy A, et al. Management of cerebral metastasis: evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. Eur J Cancer 2011; 47:649-655.
8. Taillibert S, Laigle-Donadey F, Sanson M. Palliative care in patients with primary brain tumors. Curr Opin Oncol 2004; 16:587-592.
9. Taillibert S, Delattre JY. Palliative care in patients with brain metastases. Curr Opin Oncol 2005; 17:588-592.
10. Batchelor TT, Byrne TN. Supportive care of brain tumor patients. Hematol Oncol Clin North Am 2006; 20:1337-1361.
11. Catt S, Chalmers A, Fallowfield L. Psychosocial and supportive-care needs in high-grade glioma. Lancet Oncol 2008; 9:884-891.
12. Gofton TE, Graber J, Carver A. Identifying the palliative care needs of patients living with cerebral tumors and metastases: a retrospective analysis. J Neurooncol 2012; 108:527-534.
13. Barnes EA, Chow E, Tsao MN, et al. Physician expectations of treatment outcomes for patients with brain metastases referred for whole brain radiotherapy. Int J Radiat Oncol Biol Phys 2010; 76:187-192.
14. Temel JS, Greer JA, Admane S, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic nonsmall-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol 2011; 29:2319-2326.
15. Ford E, Cat S, Chalmers A, Fallowfield L. Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro Oncol 2012; 14:392-404.
16. Becker G, Hatami I, Xander C, et al. Palliative cancer care: an epidemiologic study. J Clin Oncol 2011; 29:646-650.
17. Stone CA, Lawlor PG, Sawa GM, et al. Prospective study of falls and risk factors for falls in adults with advanced cancer. J Clin Oncol 2012; 30:2128-2133.
18. Yamanaka R, Koga H, Yamamoto Y, et al. Characteristics of patients with brain metastases from lung cancer in a palliative care center. Support Care Cancer 2011; 19:467-473.
19. Gathinji M, Mc Girt MJ, Attenello FJ, et al. Association of preoperative depression and survival after resection of malignant brain astrocytoma. Surg Neurol 2009; 71:299-303.
20. Mainio A, Hakko H, NiemeläA, Koivukangas J, Räsänen P. Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry 2006; 21:194-199.
21. Kerr CW, Drake J, Milch RA, et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 2012; 43:68-77.
22. Prommer E. Methylphenidate: established and expanding roles in symptom management. Am J Hosp Palliat Care 2012; 29:483-490.
23. Talacchi A, Santini B, Savazzi S, Gerosa M. Cognitive effects of tumour and surgical treatment in glioma patients. J Neurooncol 2011; 103:541-549.
24. Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. Int J Radiat Oncol Biol Phys 2010; 77:662-669.
25. Hilverda K, Bosma I, Heimans JJ, et al. Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. J Neurooncol 2010; 97:89-94.
26. Cheng JX, Liu F BL, Zhang X, et al. Health-related quality of life in glioma patients in China. BMC Cancer 2010; 10:305.
27. Taillandier L, Blonski M, Darlix A, et al. Supportive care in neurooncology. Rev Neurol (Paris) 2011; 167:762-772.
28. Bosma I, Vos MJ, Heimanns JJ, et al. The course of neurocognitive functioning in high-grade glioma patients. Neuro Oncol 2007; 9:53-62.
29. Brown PD, Jenson AW, Felton SJ, et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol 2006; 24:5427-5433.
30. Weitzner MA, Meyers CA, Valentine AD. Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 1995; 7:347-350.
31. Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998; 16:2522-2527.
32. Bruera E, Brenneis C, Patterson AH, et al. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage 1989; 4:3-6.
33. Bruera E, Chadwick S, Brenneis C, et al. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 1987; 71:67-70.
34. Bruera E, Fainsinger R, Mc Eachern T, Hanson J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 1992; 50:75-77.
35. Wilwerding MB, Loprinzi CL, Mailliard JA, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer 1995; 3:135-138.
36. Vercueil L. Brain tumor epilepsy: a reappraisal and six remaining issues to be debated. Rev Neurol (Paris) 2011; 167:751-761.
37. Hildebrand J, Lecaille C, Perennes J, et al. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 2005; 65:212-215.
38. Lee JW, Wen PY, Hurwitz S, et al. Morphological characteristics of brain tumors causing seizures. Arch Neurol 2010; 67:336-342.
39. Sperling MR, Ko J. Seizures and brain tumors. Semin Oncol 2006; 33:333-341.
40. Stevens GH. Antiepileptic therapy in patients with central nervous system malignancies. Curr Neurol Neurosci Rep 2006; 6:311-318.
41. Kargiotis O, Markoula S, Kyritsis AP. Epilepsy in the cancer patient. Cancer Chemother Pharmacol 2011; 67:489-501.
42. Rossetti AO, Stupp R. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 2010; 74:1329.
43. Jaeckle KA, Ballman K, Furth A, et al. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 2009; 73:1207-1213.
44. Caissie A, Culleton S, Nguyen J, et al. EORTC QLQ-C15-PAL quality of life scores in patients with advanced cancer referred for palliative radiotherapy. Support Care Cancer 2012; 20:841-848.
45. Gerrard GE, Prestwich RJ, Edwards A, et al. Investigating the palliative efficacy of whole-brain radiotherapy for patients with multiple-brain metastases and poor prognostic features. Clin Oncol (R Coll Radiol) 2003; 15:422-428.
46. Roos DE, Wirth A, Burmeister BH, et al. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiother Oncol 2006; 80:318-322.
47. Wong J, Hind A, Kirou-Mauro A, et al. Quality of life in brain metastases radiation trials: a literature review. Curr Oncol 2008; 15:25-45.
48. Yaneva MP, Semerdjieva MA. Assessment of the effect of palliative radiotherapy for cancer patients with intracranial metastases using EORTC-QOLC30 questionnaire. Folia Med (Plovdiv) 2006; 48:23-29.
49. Mauer ME, Taphoorn MJ, Bottomley A, et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. J Clin Oncol 2007; 25:5731-5737.
50. Groenvold M, Petersen MA, Aaoronson NK, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 2006; 42:55-64.
51. Colen CB, Allcut E. Quality of life and outcomes in glioblastoma management. Neurosurg Clin N Am 2012; 23:507-513.
52. Herdman M. The measurement of health related quality of life. Med Clin (Barc) 2000; 114 (Suppl 3):22-25.
53. Steinmann D, Paelecke-Habermann Y, Geinitz H, et al. Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases. BMC Cancer 2012; 12:283.
54. O'Hara RE, Hull JG, Lyons KD, et al. Impact on caregiver burden of a patientfocused palliative care intervention for patients with advanced cancer. Palliat Support Care 2010; 8:395-404.
55. Brown PD, Decker PA, Rummmans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: comparison of patient and caregiver ratings of quality of life. Am J Clin Oncol 2008; 31:163-168.
56. Brown AL, Beatty JA, Lindsay SA, et al. Severe systemic hypertension in a cat with pituitary-dependent hyperadrenocorticism. J Small Anim Pract 2012; 53:132-135.
57. Bruera E, Bush SH, Willey J, et al. Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer 2009; 115:2004-2012.
58. Cohen MZ, Pace EA, Kaur G, et al. Delirium in advanced cancer leading to distress in patients and family caregivers. J Palliat Care 2009; 25:164-171.
59. Oberndorfer S, Lindeck-Pozza E, Lahrmann H, et al. The end-of-life hospital setting in patients with glioblastoma. J Palliat Med 2008; 11:26-30.
60. Schubart JR, Kinzie MB, Farace E. Caring for the brain tumor patient: family caregiver burden and unmet needs. Neuro Oncol 2008; 10:61-72.
61. Pinquart M, Sorensen S. Differences between caregivers and noncaregivers in psychological health and physical health: a meta-analysis. Psychol Aging 2003; 18:250-267.
62. Elwert F, Christakis NA. The effect of widowhood on mortality by the causes of death of both spouses. Am J Public Health 2008; 98:2092-2098.
63. Schulz R, Beach SR. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA 1999; 282:2215-2219.
64. Lipsman N, Skanda A, Kimmelman J, et al. The attitudes of brain cancer patients and their caregivers towards death and dying: a qualitative study. BMC Palliat Care 2007; 6:7.
65. Balducci M, Chiesa S, Diletto B, et al. Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study. Neuro Oncol 2012; 14:79-86.
66. Malmstrom A, Gronberg GH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13:916-926.